GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stereotaxis Inc (AMEX:STXS) » Definitions » Operating Margin %
中文

Stereotaxis (Stereotaxis) Operating Margin %

: -116.19% (As of Dec. 2023)
View and export this data going back to 2004. Start your Free Trial

Operating Margin % is calculated as Operating Income divided by its Revenue. Stereotaxis's Operating Income for the three months ended in Dec. 2023 was $-5.30 Mil. Stereotaxis's Revenue for the three months ended in Dec. 2023 was $4.57 Mil. Therefore, Stereotaxis's Operating Margin % for the quarter that ended in Dec. 2023 was -116.19%.

Warning Sign:

Stereotaxis Inc operating margin has been in a 5-year decline. The average rate of decline per year is -57.6%.

The historical rank and industry rank for Stereotaxis's Operating Margin % or its related term are showing as below:

STXS' s Operating Margin % Range Over the Past 10 Years
Min: -81.58   Med: -19.5   Max: -8.37
Current: -81.58


STXS's Operating Margin % is ranked worse than
75.34% of 815 companies
in the Medical Devices & Instruments industry
Industry Median: 1.28 vs STXS: -81.58

Stereotaxis's 5-Year Average Operating Margin % Growth Rate was -57.60% per year.

Stereotaxis's Operating Income for the three months ended in Dec. 2023 was $-5.30 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-21.84 Mil.


Stereotaxis Operating Margin % Historical Data

The historical data trend for Stereotaxis's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stereotaxis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.70 -25.21 -36.80 -66.71 -81.58

Stereotaxis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -61.03 -85.81 -67.15 -72.30 -116.19

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Stereotaxis's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stereotaxis Operating Margin % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Stereotaxis's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Stereotaxis's Operating Margin % falls into.



Stereotaxis Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Stereotaxis's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-21.839 / 26.771
=-81.58 %

Stereotaxis's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-5.304 / 4.565
=-116.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stereotaxis  (AMEX:STXS) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Stereotaxis Operating Margin % Related Terms

Thank you for viewing the detailed overview of Stereotaxis's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Stereotaxis (Stereotaxis) Business Description

Traded in Other Exchanges
Address
710 North Tucker Boulevard, Suite 110, St. Louis, MO, USA, 63101
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service and accessories stream. The company generates the majority of revenue from the United States.
Executives
Paul J Isaac 10 percent owner 530 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10036
Myriam Curet director 1020 KIFER ROAD, SUNNYVALE CA 94086
David Benfer director 5 SELDEN AVENUE, BRANFORD CT 06404
Kimberly R. Peery officer: Chief Financial Officer C/O STEREOTAXIS, INC., 4320 FOREST PARK AVENUE: SUITE 100, ST. LOUIS MO 63108
Kevin M. Barry officer: Chief Legal Officer & Secretar 4320 FOREST PARK AVENUE, 100, ST. LOUIS MO 63108
Ross B Levin director 530 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10036
Fariba Fischel Ghodsian 10 percent owner 10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
Dafna Capital Management Llc 10 percent owner 10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
David Leo Fischel director 10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
Arun Swarup Menawat director 2412 EIGHTH LINE, OAKVILLE A6 L6H6S9
Joe E Kiani director 4320 FOREST PARK AVENUE, SUITE 100, ST. LOUIS MO 63108
Paul Brathwaite officer: VP Research & Development C/O STEREOTAXIS, INC., 4320 FOREST PARK AVENUE, SUITE 100, ST. LOUIS MO 63108
Martin C Stammer officer: Chief Financial Officer C/O STEREOTAXIS, INC., 4320 FOREST PARK AVENUE, SUITE 100, ST. LOUIS MO 63108
Nathan Fischel director 10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
Duane Desisto director C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730